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Background & aims: Acute pancreatitis is a systemic immunoinﬂammatory response to auto-digestion of
the pancrease and peri-pancreatic organs. Patients with acute pancreatitis can rapidly develop nutri-
tional deﬁciency; hence nutritional support is important and critical. Sometimes parenteral nutrition
(PN) is inevitable in acute pancreatitis. Due to immunosuppressive and inﬂammatory nature of the
disease, it seems that immunonutrients like glutamine and omega-3 fatty acids (u-3 FAs) added to
parenteral formulas may improve the conditions. We conducted a meta-analysis to evaluate the effects of
parenteral immunonutrition on clinical outcomes (infectious complications, length of hospital stay (LOS)
and mortality) in patients with acute pancreatitis.
Methods: A computerized literature search on four databases (PubMed, Cochrane, ISI Web of Science, and
Iran Medex) was performed to ﬁnd all the randomized controlled trials (RCTs) assessed the effects of
parenteral immunonutrition in acute pancreatitis. Necessary data were extracted and quality assessment
of RCTs was performed with consensus in the study team. Fixed effects model was used to conduct the
meta-analysis.
Results: One hundred and ninety four references were found via our search in which 7 articles matched
our criteria for enrolling the meta-analysis. Parenteral immunonutrition signiﬁcantly reduced the risk of
infectious complications (RR ¼ 0.59; 95% CI, 0.39e0.88; p  0.05) and mortality (RR ¼ 0.26; 95% CI, 0.11
e0.59; p  0.001). LOS was also shorter in patients who received immunonutrition (MD ¼ 2.93 days;
95% CI, e4.70 to 1.15; p  0.001).
Conclusion: Immunonutrients like glutamine and u-3 FAs added to parenteral formulas can improve
prognoses in patients with acute pancreatitis.
© 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Acute pancreatitis is a systemic immunoinﬂammatory response
to auto-digestion of the pancrease and peri-pancreatic organs.
Gallstone and alcohol abuse (usually in men) are the most impor-
tant causes of acute pancreatitis. The disease is revealed clinically in
different patterns ranging frommild forms to severe necrosis of the
gland [1].nutrition; ICU, intensive care
f stay in hospital; MD, mean
omized controlled trial; RR,
ror.
for Clinical Nutrition and MetabolPatients with acute pancreatitis can rapidly develop nutritional
deﬁciencies due to organs dysfunctions and systemic inﬂamma-
tion; hence nutritional support is very important and even would
be critical if the patients had been in malnourished situation before
attack [2]. The main predictors of the patients outcomes are: (i)
severity of the disease, and (ii) nutritional status of the patients [3].
There is no speciﬁc treatment for acute pancreatitis. In most mild to
moderate cases, condition of patients improves spontaneously in a
week. During this time, monitoring and supportive treatments such
as endoscopic retrograde cholangiopancreatography (ERCP; only in
gallstone pancreatitis), intravenous rehydration, and oxygenation
may ameliorate the condition [2,4]. Patients with severe acute
pancreatitis require more intensive care. Nutritional support is
more important and critical due to the signiﬁcant risk of malnu-
trition in such patients [5].ism. All rights reserved.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e4336Until the late 1990s, it was believed that the best way to control
the condition of patients with acute pancreatitis is gut rest with or
without parenteral nutrition (PN) [5]. Recently, the body of evi-
dence has been increased regarding the use of enteral nutrition
(EN) in acute pancreatitis because gut is working [6]. According to
the International Consensus Guidelines for Nutrition Therapy in
Pancreatitis-2012, EN is preferred over PN in patients with acute
pancreatitis. The committee has stated that PNmust be restricted to
situations in which EN is contraindicated or not feasible (for
example when it is difﬁcult to install the feeding tube correctly or
when the patients cannot tolerate EN), or as a supplementary
therapy when EN cannot provide full nutritional support [7]. In
addition to the severity of pancreatitis and presence or absence of
necrosis or pseudocycts, conditions like ileus or colonic perforation
enforce us to choose PN [8,9].
Owing to immunosuppressive and hyper inﬂammatory nature
of acute pancreatitis, the immune-enhanced products can be useful
to improve the immune responses andmodulation of inﬂammation
if these products are used enterally or parenterally [6,10,11].
Immunomodulating diets (IMDs) contain immunonutrients such as
glutamine or omega-3 fatty acids (u-3 FAs) that have demonstrated
beneﬁcial effects on immune system in experimental models [12].
Glutamine improves lymphocyte functions and contributes to anti-
oxidative defenses. It can also support the intestinal integrity and
decrease bacterial translocation; hence reduce systemic inﬂam-
matory responses and sepsis, which are important in critical ill-
nesses such as acute pancreatitis [13]. Omega-3 fatty acids may
ameliorate the condition of critically ill patients by modulating the
production of inﬂammatory eicosanoids and cytokines; therefore,
improve several physiological functions such as immune response,
cell proliferation, blood clotting, and inﬂammation [14]. No adverse
effects of the use of u-3 FAs in parenteral formulas have been re-
ported, but there are few studies in this subject to make a strong
deduction. However, there are some evidences asserting that high
dosages of u-3 FAs (5 g/d) may increase glucose level, bleeding
time, and production of low-density-lipoprotein cholesterol [15,16].
Several meta-analyses failed to produce convincing evidence on
the beneﬁcial effects of immunomodulating parenteral nutrition in
clinical outcomes of critically ill patients [17e20]. It is important to
note that the clinical response depends on the parenteral formula,
illness background and severity [5]. Previousmeta-analyses grouped
different immunomodulating formulas and different types of pa-
tients together [18e20]. It may lead to heterogeneity and perhaps
masking treatment effects [21]. Therefore, this studyaims to evaluate
the clinical outcomes of immunoparenteral vs. standard parenteral
nutrition inpatientswith acute pancreatitis byquantitative reviewof
randomized controlled trials (RCTs) published in this ﬁeld.
2. Materials and methods
2.1. Literature search and selection
The project was registered in PROSPERO, international pro-
spective register of systematic reviews with the registration num-
ber: CRD 42013004746.We followed PRISMA criteria to conduct the
systematic review and also to report the results of meta-analysis of
RCTs [22]. The method and eligibility criteria were documented as a
protocol submitted to PROSPERO that was available at the
mentioned database. A computerized literature search on four da-
tabases (PubMed, Cochrane register of control trials, ISI Web of
Science, and Iran Medex) was performed. After achieving
consensus within study team on search strategy, RCTs published
until June 2013 were identiﬁed.
The search strategy for PubMed was: (“acute pancreatitis”[tiab]
OR “pancreatitis”[tiab] OR “acute necrotizing pancreatitis”[tiab])AND (“nutritional support”[tiab] OR” dietary supplementa-
tion”[tiab] OR “parenteral nutrition”[tiab] OR “total parenteral
nutrition”[tiab] OR “parenteal nutrition solutions”[tiab] OR
“immunonutrition”[tiab]) AND (“Fatty Acids, Omega-3”[Mesh] OR
“Fish oil”[tiab] OR “glutamine”[tiab] OR “glutamine dipeptides”[-
tiab] OR “L-glutamine”[tiab] OR “glutamine supplementa-
tion”[tiab]). We decided to search other databases with the key
words: “parenteral nutrition” AND “acute pancreatitis”. Three au-
thors evaluated the total identiﬁed articles separately through
study of the titles, abstracts, and if necessary, full texts. An addi-
tional search was done on the references of the probable related
literature to avoidmissing articles. The eligibility criteria for articles
to be selected were parallel-group RCTs in which a parenteral
immunonutrition solution was compared with standard form in
patients with acute pancreatitis.
2.2. Inclusion and exclusion criteria
Among the articles with the subject of parenteral nutrition in
acute pancreatitis, we selected those consistent with the inclusion
and exclusion criteria:
Inclusion criteria:
- RCTs which used parenteral immunonutrition containing
glutamine or glutamine dipeptide and compared its effects with
standard parenteral nutrition on clinical outcomes of patients
with acute pancreatitis.
- RCTs which used parenteral immunonutrition containing u-3
FAs or ﬁsh oil and compared its effects with standard parenteral
nutrition on clinical outcomes of patients with acute
pancreatitis.
- Both parenteral immunonutrition solution and standard form
had to be iso-caloric and also iso-nitrogenus.
- Patients involved were females or males aged 16 or over, with
acute pancreatitis whom needed PN therapy, and the parenteral
feeding had begun within 72 h after admittance to ICU.
- RCTs that had our desirable clinical outcomes (infectious com-
plications, mortality rate, or LOS).
Trials were included regardless of glutamine or u-3 FAs doses,
and patients could receive additional ﬂuid and electrolytes via
supplementation therapy.
Exclusion criteria:
- RCTs evaluated EN, or compared EN with PN.
- RCTs evaluated parenteral immunonutrition in any other con-
dition except acute pancreatitis or gathered all critically ill-
nesses together.
2.3. Quality assessment
Two authors independently assessed the quality of selected ar-
ticles using modiﬁed Jadad score [23]. Intention-to-treat and use of
blinded endpoints were added according to Bollhalder et al. [20],
with a minor modiﬁcation in scoring. Each question scored 1 for
“Yes”, and 0 for “No” answer, thus our new scoring was ranged from
0 to 7. The quality score was not used to exclude the articles; it was
used to explain the probable heterogeneity of the results and to
achieve a more logical deduction. Final scores were discussed
within the study team to consent about doubtful points.
The quality of the evidence for each outcome was assessed ac-
cording to Grades of Recommendation, Assessment, Development,
and Evaluation (GRADE)Working Group using GRADE pro software
version 3.6. The criteria assessed in each study were consistency
and precision of data, directness, the study design and potential
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T. Jafari et al. / Clinical Nutrition 34 (2015) 35e43 37limitations, as well as sample and effect sizes. Finally, the quality of
evidencewas categorized as high, moderate, low, and very low [24].
2.4. Data extraction
We designed a data extraction table which contained the
mentioned information: quality score of the studies, methods of
severity assessment, sorts of interventions and dosages, the interval
between admittance to ICU and start of PN, duration of PN, and all
relevant outcome measures (Table 1).
To extract the data on length of hospital stay, we estimated
mean and standard deviation from median and sample size where
necessary, according to Hozo et al. [25]. Data extraction process was
performed with consensus in the study team.
2.5. Statistical analysis
The association between parenteral immunonutrient-enriched
formulas (glutamine or u-3 FAs) with infectious complications,
mortality and LOS, were separately assessed. Main outcome var-
iables were measures of relative risks for the association between
parenteral immunonutrition levels and infectious complications
and mortality, while for LOS was mean difference ± standard
error (SE). Point estimates of relative risks (RRs) or mean ± SE and
95% conﬁdence intervals (CI) were estimated for each study.
Within and between-study heterogeneities were assessed using
Cochran's Q-statistics [26], and the heterogeneity test was used to
assess the null hypothesis that all studies evaluated the same
effect. The effect of heterogeneity was quantiﬁed using I square
(I2) that provides a measure of the degree of inconsistency be-
tween studies and determines whether the percentage of total
variation across studies is due to heterogeneity rather than
chance [27]. I2 values range between 0 and 100%, and I2 values of
25, 50 and 75% are referred to as low, moderate, and high esti-
mates, respectively. We found no evidence of heterogeneity, so
the ﬁxed effect method [28] was applied to calculate pooled
relative risks (RRs) and 95% conﬁdence intervals (CIs). The funnel
plot, Begg and Mazumdar rank correlation test and Egger test
were employed to assess the publication bias [29]. Sensitivity
analysis was conducted to explore the extent to which inferences
might depend on a particular study or number of publications.
Statistical analyses were conducted by using Stata version 11.2
(Stata Corp, College Station, TX). P values less than 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Study identiﬁcation and selection
We found a total of 194 references via our systematic search. We
excluded 130 articles with irrelative topics; the remaining 64 ref-
erences contained 31 duplications that we had to exclude them.
There remained 33 articles about the effects of PN on acute
pancreatitis, among them, 7 articles [30e36] were eligible to
include in meta-analysis. Figure 1 summarized the process.
3.2. Analysis of outcomes
The results of quality assessment of each outcome are repre-
sented in summary of ﬁndings table (Table 2). “High” indicated that
further research is unlikely to change our conﬁdence in the esti-
mate of the effect. “Moderate” indicated that further research is
likely to have an important impact on our conﬁdence in the esti-
mate of effect and may change the estimate. “Low” indicated that
Fig. 1. PRISMA ﬂow diagram of study identiﬁcation, inclusion, and exclusion.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e4338further research is likely to have an important impact on our con-
ﬁdence in the estimate of effect and is likely to change the estimate.3.3. Study characteristics
Table 1 shows essential characteristics of 7 mentioned RCTs
consisting of 266 participants enrolled in the meta-analysis. The
risk of bias for each study was assessed according to the modiﬁed
Jadad score and is presented in Table 1.3.4. Effect of parenteral immunonutrition on infectious
complications
Infectious complications were indicated in 6 of 7 studies with
226 participants and one study [33] did not report any data in this
subject. Pooled analysis of 6 trials represented that parenteral
immunonutrition can signiﬁcantly reduce the risk of infectious
complications in patients with acute pancreatitis (Fig. 2; RR ¼ 0.59;
95% CI, 0.39 to 0.88; p  0.05). The chi-squared test for heteroge-
neity was not signiﬁcant (p ¼ 0.67) and I2 was 0.0%. Moreover, no
Table 2
Summary of ﬁndings table: clinical outcomes.
Outcomes No of participants
(studies)
Quality of the
evidence (GRADE)
Relative effect (95% CI) Anticipated absolute effects
Risk with standard
parenteral nutrition
Risk difference with parenteral
immunonutrition (95% CI)
Parenteral immunonutrition compared to standard parenteral nutrition
Infectious
complications
226 (6 studies) 4442
MODERATEa due
to imprecision
RR 0.59 (0.39e0.88) 354 per 1000 145 fewer per 1000
(from 42 fewer to 216 more)
Mortality 266 (7 studies) 4442
MODERATEa due
to imprecision
RR 0.26 (0.11e0.59) 173 per 1000 128 fewer per 1000
(from 71 fewer to 154 more)
Length of
hospital stay
196 (5 studies) 4442
MODERATEa due
to imprecision
The mean
length of
hospital
stay in the
control
groups was
33.9 days
The mean length of hospital
stay in the intervention groups
was 2.93 days lower (4.7e1.15 lower)
Glutamin-contained parenteral nutrition compared to standard parenteral nutrition
Infectious
Complication
130 (4 studies) 4442
MODERATEa due
to imprecision
RR 0.56 (0.34e0.91) 400 per 1000 176 fewer per 1000
(from 36 fewer to 264 more)
Mortality 170 (5 studies) 4442
MODERATEa due
to imprecision
RR 0.34 (0.14e0.85) 176 per 1000 116 fewer per 1000
(from 26 fewer to 152 more)
Length of
hospital stay
156 (5 studies) 4442
MODERATEa due
to imprecision
The mean
length of
hospital
stay in the
control groups
was 19.8 days
The mean length of hospital
stay in the intervention groups
was 2.60 days lower (4.5e0.71
lower)
Omega 3-contained parenteral nutrition compared to standard parenteral nutrition
Infectious
Complication
96 (2 studies) 4442 MODERATEa due
to imprecision
RR 0.64 (0.31e1.34) 292 per 1000 105 fewer per 1000 (from 99
fewer to 201more)
Mortality 96 (2 studies) 4442 MODERATEa due
to imprecision
RR 0.11 (0.01e0.85) 167 per 1000 148 fewer per 1000 (from 25
fewer to 165 more)
Length of stay
in hospital
40 (1 study) 4422 LOWa,b due to
imprecision, publication bias
The mean length
of stay in hospital
in the control groups
was 70.5 days
The mean length of stay in
hospital in the intervention
groups was 5.30 days lower
(10.41e0.19 lower)
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conﬁdence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Conﬁdence interval; RR: Risk ratio.
a Low sample size in some studies may make imprecision.
b There is only 1 study for this outcome.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e43 39evidence of publication bias was found based on funnel plot (Egger
test, p ¼ 0.36).
Stratiﬁed meta-analysis was conducted to show the effect of
glutamine- or u-3 FAs-enriched formulas separately. Results rep-
resented that glutamine-contained parenteral formulas signiﬁ-
cantly attenuated infectious complications in patients with acute
pancreatitis (Fig. 2; RR ¼ 0.56; 95% CI, 0.34 to 0.91; p  0.05).
Regarding u-3 FAs-enriched formulas, the risk was reduced but the
result was not signiﬁcant (Fig. 2; RR ¼ 0.64; 95% CI, 0.31 to 1.34;
p ¼ 0.23). No evidence of between study heterogeneity was found
in glutamine subgroup (I2¼ 5.5%, p¼ 0.36) and inu-3 FAs subgroup
(I2 ¼ 0.0%, p ¼ 0.89). Also funnel plots did not show evidence of
publication bias for glutamine and u-3 FAs (Egger test, p ¼ 0.502
and p ¼ 0.33, respectively).
To show the cumulative evidence at the time of each study in
included trials from 1998 to 2009, cumulative meta-analysis was
also performed. As demonstrated in supplementary data (Fig. S1),
the risk for infectious complications reduced signiﬁcantly by the
late of 1998.
3.5. Effect of parenteral immunonutrition on mortality
All 7 studies [30e36] enrolled in meta-analysis (266 partic-
ipants) had data on mortality. Almost all of these studies hadreported a reduction in mortality in intervention group
comparing to control, but their results were not signiﬁcant. After
pooling the studies and conducting the meta-analysis, a signif-
icant association was found between parenteral immunonu-
trition therapy and mortality reduction in patients with acute
pancreatitis (Fig. 3; R ¼ 0.26; 95% CI, 0.11 to 0.59; p  0.001).
There was not any heterogeneity among the studies (I2 was 0.0%,
p ¼ 0.92); also publication bias was not conﬁrmed (Egger test,
p ¼ 0.68).
Figure 3 also represents the effects of glutamine- and u-3 FAs-
enriched parenteral formulas on mortality separately. In gluta-
mine subgroup, the risk of mortality reduced (RR ¼ 0.34; 95% CI,
0.14 to 0.85; p  0.05). The test for heterogeneity was not sig-
niﬁcant in this subgroup (I2 ¼ 0.0%, p ¼ 0.94). In u-3 FAs sub-
group, mortality incidence was reduced signiﬁcantly in patients
who had received u-3 FAs parenterally (RR ¼ 0.11; 95% CI, 0.01 to
0.85; p  0.05). The test for heterogeneity was also non-
signiﬁcant in this subgroup (I2 ¼ 0.0%, p ¼ 0.64). The funnel
plots did not show evidence of publication bias (glutamine
subgroup: Egger test, p ¼ 0.36; u-3 FAs subgroup: Egger test,
p ¼ 1).
Cumulative meta-analysis suggested that the relative risk of
mortality has been declined by the late of 1998 (Supplementary
data, Fig. S2).
..
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Fig. 2. Forest plot of effect of parenteral immunonutrition on infectious complications.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e43403.6. Effect of parenteral immunonutrition on LOS
Five records [31e35] (196 participants) among 7 studies had
data on LOS for analysis; and 2 studies (De Beaux et al. and Wang
et al.) [30,36] did not published information in this ﬁeld. As rep-
resented in Fig. 4, parenteral immunonutrition was signiﬁcantly
associated with reduction in hospitalization in acute pancreatitis
(MD ¼ 2.93 days; 95% CI, e4.70 to 1.15; p  0.001). The tests for
heterogeneity indicated that there were no heterogeneity among
the studies (I2 ¼ 28.4%, p ¼ 0.23). Also the funnel plot did not show
evidence of publication bias (Egger test, p ¼ 0.22).
Stratiﬁed meta-analysis in this ﬁeld demonstrated that both
glutamine- and u-3 FAs-enriched parenteral formulas signiﬁcantly
reduced LOS in patients with acute pancreatitis (Fig. 4; glutamine:
MD ¼ 2.60 days; 95% CI, e4.50 to 0.71; p  0.01; u-3 FAs:
MD ¼ 5.30 days; 95% CI, e10.41 to 0.19; p  0.05). The test for
heterogeneity within glutamine supplemented group was not sig-
niﬁcant (I2 ¼ 35.4%, p ¼ 0.20) and funnel plot represented that no
publication bias were existed (Egger test, p ¼ 0.29). In the other
subgroup comprising one study [35], it was not necessary to check
heterogeneity.
Considering the plot of cumulative meta-analysis on effect of
parenteral immunonutrition on LOS (Supplementary data, Fig. S3),
the most reduction in length of hospitalization was observed in the
studies of De Beaux et al. [30] andOckenga et al. [31], while regardingthe two other outcomes (infectious complications andmortality) the
trends of relative risks were descending from 1998 to 2009.
4. Discussion
Considering the contradictory results of RCTs comparing paren-
teral immunonutrition with standard PN, several meta-analyses
[18,20,37,38] have been conducted to clarify whether immune-
enhanced formulas improve condition of patients. But data from
these meta-analyses have failed to make convincing evidence. Most
of the quantitative reviews evaluated the effects of parenteral
immunonutrition in different types of diseases called critical ill-
nesses. For example, Pradelli et al. apprised the effects of u-3 FAs-
enriched parenteral regimens in elective surgical and ICU patients
and concluded that these formulas reduced infectious rate and LOS
[19]. In another meta-analysis, Bollhalder et al. evaluated the effects
of parenteral glutamine supplementation in different types of dis-
eases [20]. They classiﬁed studies to surgery and critical illnesses. The
results could not clarify whether parenteral immunonutrition
improve the condition of patients. Controversial results are also
observed in meta-analyses performed by Chen et al. [18] and Palmer
et al. [37]. They grouped the patients with conditions such as trauma,
burn, surgery, and ICU admittance as critically ill whichmay increase
heterogeneity and mask the truth. However, in some analyses criti-
cally ill patients were subgrouped according to their disease but
..
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Fig. 3. Forest plot of effect of parenteral immunonutrition on mortality.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e43 41patients admitted in ICU were still considered a single group. It
seems that subgrouping must be continued because of high het-
erogeneity of patients in ICU. Most doubt about beneﬁts of immu-
nonutrition (enterally or parenterally) exists in ICU admitted patients
[39]. It should be considered that the clinical responses depend on
the type of parenteral formula, kind of the disease, and status of
patients. These points must be considered before designing a meta-
analysis. Considering the scientiﬁc literature, this meta-analysis is
the ﬁrst which assessed parenteral immunonutrition in patients
with acute pancreatitis speciﬁcally. Petrov et al. evaluated enteral
immunonutrient-enriched formulas in acute pancreatitis in their
meta-analysis and concluded that these formulas did not have any
beneﬁcial effect on outcomes of patients [40]. Considering the lack of
sufﬁcient RCTs with adequate sample size, they recommended more
appropriate trials in patients with acute pancreatitis.
According to our meta-analysis, overall evaluation of the RCTs as
well as grouping them according to the type of formula (glutamine
or u-3 FAs) demonstrates reduction in infectious complications via
parenteral immunonutrition. Non-signiﬁcant results in u-3 FAs
group may be due to few scientiﬁc evidences performed in the
subject (only 2 studies [35,36] conducted by the same authors that
might have used the same cohort of patients). McClave et al.
designed a meta-analysis with 3 trials existed until 2006 about the
effect of glutamine-supplemented parenteral nutrition oncomplications in patients with acute pancreatitis. They found the
trend of reduction only in complications [41]. After that time, 2
more trials were performed [33,34]. Evaluation of the data from 5
trials [30e34] about glutamine demonstrates a signiﬁcant overall
effect in the present meta-analysis. Our meta-analysis clariﬁed that
immunonutrient-supplemented PN signiﬁcantly reduces the mor-
tality rate in patients with acute pancreatitis, while previous meta-
analyses which have grouped different types of patients together as
critically ill, failed to demonstrate reduction in mortality [19,37,41]
or only represented a trend toward reduction [20,42]. Length of
hospitalization reduced signiﬁcantly in groups who received any
kind of immuno-nutrients via parenteral pathway according to
recent meta-analysis. However, according to GRADE, all 3 outcomes
were appraised as moderate quality which means that further
research is likely to have an important impact on our conﬁdence in
the estimate of effect andmay change the estimate. Considering the
trend of the effect of IMDs on LOS (supplementary data, Fig. S3),
mean differences between intervention group (who received IMDs)
and controls (who did not received IMDs) have declined from 1998
to 2009. It might be due to improvement in treatment strategies of
critically ill patients including patients with acute pancreatitis.
Themedian length of parenteral feedingwas signiﬁcantly lower in
glutamine-supplemented group than control [31]. The average ICU
stay was lower in patients who received u-3 FAs than control group
Heterogeneity between groups: p = 0.332
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Fig. 4. Forest plot of effect of parenteral immunonutrition on length of stay in hospital.
T. Jafari et al. / Clinical Nutrition 34 (2015) 35e4342[35]. It was also reported that despite the increase of daily cost for
glutamine-supplementedTPN, theoverall relatedcost foreachpatient
did not differ between glutamine-supplemented and non-glutamine
supplemented groups due to the reduction of hospitalization [31].
Some limitations of our meta-analysis are as follows: (i) small
sample size in most of the studies, (ii) few number of studies on the
subject specially about u-3 FAs, (iii) possible heterogeneity in the
disease severity among the studies due to the application of different
methods for severity assessment, (iv) absence of accurate data in
some studies about antibiotic therapy which may inﬂuence the out-
comes, speciﬁcally the rate of infectious complications, and (v) lack of
information about probable supplementary therapies such as sur-
gery, drainage, and debridement that may affect the outcomes.
In conclusion, we recommendmore precise trials with adequate
sample size in this ﬁeld to make stronger deduction, and also
conducting meta-analyses in homogenous patients admitted in ICU
to evaluate the effects of IMDs in clinical outcomes.
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